Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclosporine is a cyclic undecapeptide immunosuppressant derived from the fungus Tolypocladium inflatum. It acts as a calcineurin inhibitor and is primarily used to prevent organ rejection in kidney, liver, and heart transplants. Cyclosporine is also indicated for severe active rheumatoid arthritis (when other treatments fail), severe plaque psoriasis (unresponsive to other systemic therapies), nephrotic syndrome due to glomerular diseases (including steroid-dependent or resistant cases), Crohn's disease, eczema, and as ophthalmic drops for keratoconjunctivitis sicca (dry eyes). Its mechanism involves binding to cyclophilin in T cells to form a complex that inhibits calcineurin phosphatase activity. This blocks dephosphorylation of nuclear factor of activated T cells (NF-AT), reducing transcription of cytokines such as IL-2 required for T cell activation and proliferation[1][3][6]. Cyclosporine has significantly improved outcomes in transplantation medicine by specifically suppressing lymphocyte function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclosporine.